SQZ Biotechnologies (NYSE:SQZ – Get Rating) and Adaptive Biotechnologies (NASDAQ:ADPT – Get Rating) are both small medical companies, but which one is the superior business? We’ll compare the two companies based on the strength of their dividends, earnings, profitability, institutional ownership, analyst recommendations, valuation, and risk.
Volatility & Risk
SQZ Biotechnologies has a beta of 3.73, indicating its stock price is 273% more volatile than the S&P 500. In comparison, Adaptive Biotechnologies has a beta of 1.07, indicating its stock price is 7% more volatile than the S&P 500.
Insider and Institutional Property
66.6% of the shares of SQZ Biotechnologies are held by institutional investors. In comparison, 88.1% of Adaptive Biotechnologies’ shares are held by institutional investors. 18.0% of the shares of SQZ Biotechnologies are held by company insiders. In comparison, 34.7% of Adaptive Biotechnologies’ shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments, and hedge funds believe a company will outperform the market over the long term.
This is a breakdown of the current recommendations and price targets for SQZ Biotechnologies and Adaptive Biotechnologies as reported by MarketBeat.
|sell reviews||keep ratings||Buy reviews||Strong buy recommendations||rating score|
SQZ Biotechnologies currently has a consensus price target of $40.00, indicating a potential upside of 1,073.02%. Adaptive Biotechnologies has a consensus price target of $32.00, indicating a potential upside of 328.95%. Given SQZ Biotechnologies’ stronger consensus rating and higher potential upside, analysts clearly believe SQZ Biotechnologies is cheaper than Adaptive Biotechnologies.
This table compares the net margins, return on equity and return on assets of SQZ Biotechnologies and Adaptive Biotechnologies.
|net margins||return on equity||return on investment|
evaluation and result
This table compares the gross sales, earnings per share (EPS) and valuation of SQZ Biotechnologies and Adaptive Biotechnologies.
|gross receipts||price/sales ratio||net income||earnings per share||price-earnings ratio|
|SQZ Biotechnologies||$27.10 million||3.54||-$68.74 million||($2.64)||-1.29|
|Adaptive Biotechnologies||$154.34 million||6.87||-$207.28 million||($1.62)||-4.60|
SQZ Biotechnologies has higher yields but lower revenues than Adaptive Biotechnologies. Adaptive Biotechnologies is trading at a lower price-to-earnings multiple than SQZ Biotechnologies, suggesting it’s the cheaper of the two stocks at the moment.
Adaptive Biotechnologies beats SQZ Biotechnologies on 9 of the 13 factors compared between the two stocks.
SQZ Biotechnologies company profile (received rating)
SQZ Biotechnologies Company, a clinical-stage biotechnology company, is developing cell therapies for patients suffering from cancer, autoimmune diseases, infectious diseases and other serious diseases. Its lead product candidate is SQZ-PBMC-HPV from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as monotherapy and in combination with other immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical , head and neck, anal, penile, vulva and vaginal cancer. The Company is also developing SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combination with other immuno-oncology agents. Other platforms under development include SQZ Activating Antigen Carriers; and SQZ-tolerant antigen carriers. SQZ Biotechnologies Company was founded in 2013 and is headquartered in Watertown, Massachusetts.
Adaptive Biotechnologies Company Profile (received rating)
Adaptive Biotechnologies Corporation, a commercial-stage company, is developing an immunomedicine platform for the diagnosis and treatment of various diseases. The Company offers immunoSEQ, a platform and core immune sequencing product used to answer translational research questions and discover new prognostic and diagnostic signals; and T-Detect COVID to confirm past COVID-19 infection. It also offers clonoSEQ, a clinical diagnostic product for detecting and monitoring minimal residual disease in patients with multiple myeloma, B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia, and as a CLIA-validated laboratory-developed test for patients with other lymphoid cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure T-cell immune response to vaccines. In addition, the company offers a range of clinical products and services used to diagnose, monitor and treat diseases such as cancer, autoimmune diseases and infectious diseases. It is used for life science research, clinical diagnostics and drug research. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacturing and commercialization of neoantigen-targeted T-cell therapies for the treatment of a variety of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases using a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was founded in 2009 and is headquartered in Seattle, Washington.
Receive News & Reviews for SQZ Biotechnologies Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for SQZ Biotechnologies and related companies with MarketBeat.com’s FREE daily email newsletter.